158 related articles for article (PubMed ID: 19585114)
1. Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma.
Mittra E; El-Maghraby T; Rodriguez CA; Quon A; McDougall IR; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1952-9. PubMed ID: 19585114
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma.
Iagaru AH; Mittra ES; McDougall IR; Quon A; Gambhir SS
Nucl Med Commun; 2008 Dec; 29(12):1046-51. PubMed ID: 18987524
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer.
Driscoll DO; Halpenny D; Johnston C; Sheehy N; Keogan M
Abdom Imaging; 2015 Jan; 40(1):127-33. PubMed ID: 25015401
[TBL] [Abstract][Full Text] [Related]
4. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.
Cetina L; Serrano A; Cantú-de-León D; Pérez-Montiel D; Estrada E; Coronel J; Hernández-Lucio M; Dueñas-González A
Rev Invest Clin; 2011; 63(3):227-35. PubMed ID: 21888286
[TBL] [Abstract][Full Text] [Related]
5. Validity of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for pretreatment evaluation of patients with cervical carcinoma: a retrospective pathology-matched study.
Dong Y; Wang X; Wang Y; Liu Y; Zhang J; Qian W; Wu S
Int J Gynecol Cancer; 2014 Nov; 24(9):1642-7. PubMed ID: 25268748
[TBL] [Abstract][Full Text] [Related]
6. [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up].
Hu YY; Sun XR; Lin XP; Liang PY; Zhang X; Fan W
Ai Zheng; 2009 Sep; 28(9):994-9. PubMed ID: 19728921
[TBL] [Abstract][Full Text] [Related]
7. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
Yilmaz M; Adli M; Celen Z; Zincirkeser S; Dirier A
Nucl Med Commun; 2010 Jun; 31(6):526-31. PubMed ID: 20215979
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Prediction of local relapse and distant metastasis in patients with definitive chemoradiotherapy-treated cervical cancer by deep learning from [
Shen WC; Chen SW; Wu KC; Hsieh TC; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yen KY; Kao CH
Eur Radiol; 2019 Dec; 29(12):6741-6749. PubMed ID: 31134366
[TBL] [Abstract][Full Text] [Related]
11. Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease?
Signorelli M; Guerra L; Montanelli L; Crivellaro C; Buda A; Dell'Anna T; Picchio M; Milani R; Fruscio R; Messa C
Gynecol Oncol; 2011 Nov; 123(2):236-40. PubMed ID: 21855972
[TBL] [Abstract][Full Text] [Related]
12. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma.
Kumar R; Sharma P; Kumari A; Halanaik D; Malhotra A
Clin Nucl Med; 2012 May; 37(5):431-5. PubMed ID: 22475890
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
[TBL] [Abstract][Full Text] [Related]
14. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?
Abgral R; Querellou S; Potard G; Le Roux PY; Le Duc-Pennec A; Marianovski R; Pradier O; Bizais Y; Kraeber-Bodéré F; Salaun PY
J Nucl Med; 2009 Jan; 50(1):24-9. PubMed ID: 19091901
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
16. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer.
Wong TZ; Jones EL; Coleman RE
Mol Imaging Biol; 2004; 6(1):55-62. PubMed ID: 15018829
[TBL] [Abstract][Full Text] [Related]
18. Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer.
Chung HH; Nam BH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1467-73. PubMed ID: 20352210
[TBL] [Abstract][Full Text] [Related]
19. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
20. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma.
Pallardy A; Bodet-Milin C; Oudoux A; Campion L; Bourbouloux E; Sagan C; Ansquer C; Testard A; Resche I; Bridji B; Kraeber-Bodéré F; Rousseau C
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1270-8. PubMed ID: 20306032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
